Medicamen Biotech Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue growth shows upward trend with latest quarter at ₹44.74 Cr, indicating strong demand.
Improved operating profit margin in recent quarters, showcasing operational efficiency.
Net profit rebounded to ₹2.92 Cr in latest quarter, signaling recovery after previous lows.

NEGATIVES

Profit dropped to ₹0.90 Cr in Q2 2024, indicating potential profit margin pressures.
Expenses surged notably in recent quarters, impacting overall profitability.
Tax percentage increased significantly to 53.78% in Q2 2024, affecting net profit margins.

Field	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Jun 25
Revenue	41.94	43.54	46.50	47.32	43.05	44.74	45.14	43.05
Expenses	37.64	41.63	44.06	45.23	42.08	43.08	41.41	41.38
Operating Profit	4.30	1.91	2.44	2.09	0.97	1.67	3.74	1.66
Other Income	0.38	0.55	0.83	0.57	0.59	0.29	0.14	0.47
Interest	0.96	0.91	0.65	1.89	0.71	1.04	0.76	1.15
Depreciation	1.69	1.82	1.81	1.77	1.77	2.61	2.21	1.80
Profit Before Tax	4.68	2.46	3.27	2.66	1.56	1.96	3.88	2.13
Tax	0.74	0.99	1.24	0.61	0.76	1.05	0.96	0.53
Net Profit	3.95	1.48	2.03	2.04	0.80	0.90	2.92	1.60
Eps in Rs	3.12	1.17	1.60	1.61	0.63	0.71	2.30	1.18